

## Evaluation Report for Category L, Subcategory 1.2 Application

**Application Number:** 2023-2541

**Application:** Application Subject to Protection of Proprietary Interests in

Pesticide Data (PPIP) Policy – Equivalency/Data Compensation

Assessment

**Applicant:** Sharda Cropchem Limited **Product:** Sharda Captan 48 SC

Registration Number: 32300 Active ingredient (a.i.): Captan PMRA Document Number: 3606219

# **Purpose of Application**

The purpose of this application was to amend the registration of the end-use product, Sharda Captan 48 SC, by adding several pests and crops, based on a registered precedent product.

## **Chemistry Assessment**

Sharda Captan 48 SC is formulated as a suspension containing captan at a concentration of 480 g/L. This end-use product has a density of 1.153 g/mL and pH of 3-4. The chemistry requirements for this product have been fulfilled.

## **Health Assessments**

The use pattern of Sharda Captan 48 SC is comparable to the registered use pattern of the precedent product. Therefore, potential exposure for mixers, loaders, applicators, bystanders and postapplication workers is not expected to exceed the current exposure to the registered products of captan. No health risks of concern are expected for workers and bystanders when label directions, precautions and restrictions are followed.

No new residue data for captan were submitted or were required to support the amendments to the registered label of Sharda Captan 48 SC. Previously reviewed residue data were re-assessed in the framework of this application.

The use directions on the Sharda Captan 48 SC label, including the target crops, methods, rates and timing of application, and preharvest intervals are comparable to those on the label of the precedent product.



Based on this assessment, residues are not expected to be greater than those from the currently registered uses and will be covered by the established maximum residue limits (MRLs). Consequently, dietary exposure to residues of captan is not expected to increase with the amendment to the registration of Sharda Captan 48 SC and will not pose health risks of concern to any segment of the population, including infants, children, adults and seniors.

A toxicological assessment was not required for this application.

#### **Environmental Assessment**

The use pattern of Sharda Captan 48 SC is currently within the registered use pattern for captan. Therefore, the risk is acceptable when Sharda Captan 48 SC is used in accordance with the label, which includes statements to mitigate risks to the environment.

## **Value Assessment**

The formulation of Sharda Captan 48 SC was compared to that of the precedent product. Based on this comparison, it was concluded that these products are expected to perform similarly, both in terms of efficacy and crop tolerance. Therefore, the evidence of value for use claims included in the registration of the precedent product is acceptable for extrapolation to support comparable claims on the Sharda Captan 48 SC label.

This label expansion of Sharda Captan 48 SC will provide Canadian growers with an additional product to manage common and economically important diseases on several crops and use sites.

## **Conclusion**

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to amend the registration of Sharda Captan 48 SC.

# References

<b>PMRA</b>	Reference
<b>Document</b>	
Number	
3473045	2023, DACO 10 Sharda Captan 48 SC Fungicide, DACO: 10.1,10.2.1, 10.2.2,10.2.3.1,10.2.3.3(D),10.3,10.3.2,10.3.2(B),10.4,10.5,10.5.1,10.5.2
3473046	2023, Waiver Request-Various Crops-Sharda Captan 48 SC, DACO: 10.2.3.1,10.2.3.3,10.3.1,10.3.2

# © His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2024

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.